Ultime notizie per Gateway Bank F S B (OTC:GWBK) Azioni

Gateway Bank F S B Oakland Calif is a United States based company engaged in providing personal and business banking services. The company aims to provide banking services to people and communities who are underserved by mainstream commercial banks and lenders. These services include Checking Accounts, Savings Accounts, Money Market Accounts, Certificate of Deposit Accounts, and Individual Retirement Accounts among others.

GATEWAY BK FSB OAKLND CA by GATEWAY BK F S B OAKLAND CALIF

Gateway Bank F S B Oakland Calif

<ul>
<li>Oral Presentation Presented at ASH 2024 Showed Iopofosine I 131 Achieved an 83.6% ORR and Exceeded Primary and Secondary Efficacy Endpoints in Phase 2 CLOVER-WaM Study for Relapsed/Refractory Waldenstrom's Macroglobulinemia</li>
<li>Plans to Advance Iopofosine I 131 Internally, Through Strategic Partnerships and Other Approaches; Finalizing Confirmatory Study and Pathway for US FDA Accelerated Approval and EMA Prime Marketing Authorization</li>
<li>Advancing Radiotherapeutic Assets including Alpha- and Auger-emitting Radioconjugates into Phase 1/2a Solid Tumor Studies</li>
</ul>

News

CLRB

Reported Earlier, Cellectar Highlights Path Toward Accelerated Approval For Iopofosine I 131 and Expands Radioconjugate Development

Reported Earlier, Medical Properties Trust Supports Prospect's Chapter 11 Sale Plans For Connecticut Hospitals

Telix will acquire these assets through an asset purchase agreement with a concurrent technology license agreement to be signed at closing. The purchase price for the transaction is US$45 million (AU$73 million)3, comprised of US$10 million in cash and US$31 million in equity at closing, and a deferred payment of up to US$4 million in equity at the conclusion of a 15-month indemnity period. Upon achievement of specific key development and commercial milestones, Telix will pay up to a total of US$185 million (AU$299 million), a portion of which may be paid in cash or equity at Telix's election4. Royalties are also payable on net sales in the low single digits on a limited number of platform and early-stage products after the first four products have been developed, as well as single-digit sublicense fees, as applicable.&nbsp;&nbsp;

Reported Earlier, Telix To Acquire Imaginab's Drug Candidates And Cutting-Edge Antibody Engineering Platform For $45M

Defense giant Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) has donated $1 million to President-elect Donald Trump&#8217;s inaugural committee, maintaining its tradition of inaugural support amid rising competition from technology companies in the defense sector.
What Happened: The donation, made Dec. 2, mirrors Lockheed&#8217;s previous contributions to both Trump&#8217;s 2017 and President Joe Biden&#8216;s 2020 inaugurations, CBS News <a href="https://www.cbsnews.com/news/lockheed-martin-donates-1-million-inaugural-committee/">reported</a> on Friday. The aerospace firm, valued at over $110 billion, reported $67.6 billion in net sales for 2023 under CEO Jim Taiclet.
This contribution comes as Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) and Anduril Industries <a href="https://www.benzinga.com/markets/equities/24/12/42640010/palantir-and-anduril-reportedly-lead-consortium-partner-with-spacex-and-openai-to-compete-against-traditional-defense-contractors-in-850-billion-us-military-market">reportedly lead a new tech consortium</a>, challenging traditional defense contractors&#8217; grip on the $850 billion U.S. military market. The group, which may include SpaceX and OpenAI, plans to announce formal agreements in January.
Palantir&#8217;s market capitalization has surged to $155 billion, surpassing Lockheed Martin&#8217;s valuation. The data analytics company&#8217;s shares soared more than 50% following Trump&#8217;s election victory, despite a recent 11.78% year-to-date decline.
See Also: <a href="https://www.benzinga.com/25/01/42937761/singapore-restricts-residents-from-using-prediction-platform-polymarket-over-gambling-law-violation">Singapore Cracks Down On Polymarket: Regulator Issues Warning Against &#8216;Illegal Gambling&#8217;</a>
Why It Matters: Adding pressure on traditional contractors, Trump&#8217;s appointed Department of Government Efficiency (DOGE) co-lead, Elon Musk, recently criticized Lockheed&#8217;s F-35 fighter program, advocating for drone warfare over the $1.8 trillion <a href="https://www.benzinga.com/news/24/11/42157649/trumps-doge-co-lead-elon-musk-slams-lockheed-martins-f-35-fighter-jets-advocates-drone-warfare-as-pentagon-defends-1-8-trillion-program">manned aircraft initiative</a>.
The inaugural committee has secured over $170 million for January events, including a reception at the National Gallery of Art and The Starlight Ball at Union Station. Other major tech donors include Meta Platforms Inc., Microsoft Corp., Amazon.com Inc., Alphabet Inc.&#8216;s Google, and Apple Inc.
Wedbush Securities analyst Dan Ives predicts 2025 will be a breakthrough year for tech companies in defense, as the sector increasingly emphasizes AI-powered solutions and autonomous systems over <a href="https://www.benzinga.com/markets/equities/24/12/42696805/palantir-touted-as-next-oracle-by-dan-ives-here-is-why-the-wedbush-analyst-called-the-company-a-table-pounder">traditional military hardware</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/space/25/01/42937555/jeff-bezos-says-he-takes-elon-musk-at-face-value-despite-his-close-ties-to-trump-dismisses-concerns-about-spacex-undercutting-blue-origin">Jeff Bezos Says He Takes Elon Musk At &#8216;Face Value&#8217; Despite His Close Ties To Trump, Dismisses Concerns About SpaceX Undercutting Blue Origin</a></li>
</ul>
Image Via Lockheed Martin
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Markets

PLTR

Lockheed Martin Donates $1M To Trump's Inaugural Committee As Speculation Grows Over Elon Musk-Led DOGE Crackdown On Traditional Defense Contracts

Expects total fourth-quarter revenue of $713 million, an increase of 10% compared to the fourth quarter of 2023, with Screening revenue of $553 million and Precision Oncology revenue of $161 millionAnticipates total
<ul>
<li>Expects total fourth-quarter revenue of $713 million, an increase of 10% compared to the fourth quarter of 2023, with Screening revenue of $553 million and Precision Oncology revenue of $161 million</li>
<li>Anticipates total full-year 2024 revenue of $2.76 billion, an increase of 10% compared to full-year 2023</li>
<li>Plans to launch three new cancer tests in 2025: Cologuard PlusTM, next-generation colorectal cancer screening test, OncodetectTM, molecular residual disease test, and CancerguardTM, multi-cancer screening test</li>
</ul>

EXAS

Reported Earlier, Exact Sciences Reports Preliminary 2024 Results: Expects $2.76B In Annual Revenue (+10% YoY) And $713M In Q4 Revenue (+10% YoY)

Justin Trudeau said on Sunday that the country is poised to impose counter-tariffs should Donald Trump initiate a trade conflict. 
What Happened: Trudeau stressed that while Canada does not desire a trade war, it is prepared to retaliate if the U.S. imposes tariffs on Canadian goods. The outgoing Canadian prime minister made this announcement during an appearance on <a href="https://www.msnbc.com/inside-with-jen-psaki/watch/trudeau-we-are-ready-to-respond-with-tariffs-as-necessary-trudeau-responds-to-president-elect-trump-228990533694">MSNBC's</a> Inside With Jen Psaki.
The U.S. Commerce Department data indicates that Canada is the largest purchaser of U.S. products, with purchases amounting to approximately $320 billion last year.
In 2018, when the Trump administration levied tariffs on steel and aluminum, Canada responded by imposing tariffs on U.S. goods such as household appliances and whiskey. Bloomberg reported earlier that a draft retaliation plan could target nearly all U.S. imports to Canada.
"As we did last time, we are ready to respond with tariffs as necessary,"&nbsp;he said.
Trudeau also mentioned Canada&#8217;s increased spending on border security to address U.S. concerns about illegal migration and fentanyl. He dismissed Trump&#8217;s comments about annexing Canada as a distraction from more pressing issues.
Meanwhile, Alberta Premier Danielle Smith met with Trump to discuss the U.S.-Canada energy relationship, as over half of U.S. crude imports come from Canada. Foreign Affairs Minister Mélanie Joly stated that all options regarding energy supplies are being considered.
Why It Matters: The backdrop to this situation involves a series of events that have heightened tensions between the U.S. and Canada. In early January, Trump suggested that Canada could become <a href="https://www.benzinga.com/news/events/25/01/42860583/trump-floats-canada-as-51st-us-state-says-hes-ready-to-use-economic-force-to-achieve-it">the 51st U.S. state</a>, criticizing trade imbalances and subsidies. 
In response, a Canadian official humorously suggested buying two American states,<a href="https://www.benzinga.com/news/global/25/01/42902618/canadian-official-claps-back-at-trumps-51st-state-comments-offers-to-buy-these-two-american-states"> highlighting the strained relations</a>. Furthermore, Trudeau had <a href="https://www.benzinga.com/media/24/11/42252924/canadian-pm-justin-trudeau-warns-trumps-25-tariff-plan-will-hurt-americans-at-high-stakes-dinner">previously warned Trump </a>about the adverse effects of his proposed 25% tariff plan during a high-stakes dinner in November. 
Adding to the complexity, Trudeau<a href="https://www.benzinga.com/25/01/42823979/canadas-pm-justin-trudeau-steps-down-amid-internal-conflict-and-tension-over-trump-tariffs"> announced his resignation</a> amid internal conflict and tension over Trump tariffs. 
Read Also: 
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/42937389/tesla-hikes-model-3-y-prices-in-canada-by-c1000-after-announcing-price-increase-in-china">Tesla Hikes Model 3, Y Prices In Canada By C$1000 After Announcing Price Increase In China</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Flickr/ World Economic Forum

General

Justin Trudeau Says Canada Is 'Ready To Respond With Tariffs As Necessary' Amid Potential Trump Trade War

<ul>
<li>-- CB-010 GALLOP Phase 1 trial initiated in lupus --</li>
<li>-- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 --</li>
<li>-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 --</li>
<li>-- Sri Ryali appointed chief financial officer --</li>
</ul>

CRBU

Reported Earlier, Caribou Biosciences Advances CB-010, CB-011, And CB-012 Programs With Key Clinical Updates Expected In 2025; Cash Position $281M

Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, announced today CE (Conformité Européenne) Mark approval in the European Union (EU) and the United Kingdom (UK) for BrainSense&#x2122; Adaptive deep brain stimulation (aDBS) and BrainSense&#x2122; Electrode Identifier (EI), having achieved the standards required by the EU Medical Device Regulation (MDR). In addition, the first programming was completed today, performed by Martijn Beudel, MD, PhD, neurologist and associate professor, Department of Neurology, Amsterdam University Medical Center. This landmark approval and first-in-Europe patient programming demonstrate significant advancements in personalized DBS therapy for people with Parkinson's in Europe, including the UK.

Government

Regulations

Medtronic Gains CE Mark Approval for BrainSense Adaptive DBS, Advancing Parkinson's Treatment in Europe and UK

2024 revenues are expected to increase by approximately 56% compared to 2023, which is approximately $53 million above top end of financial outlook
Additional business updates to be presented by Natera at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

NTRA

Natera Reports Preliminary 2024 Results: $1.7B In Annual Revenue (+56% YoY), $472M In Q4 Revenue (+52% YoY), And $86.3M In Positive Cash Flow For 2024

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLX#NASDAQ">TLX</a>, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4 2024).
Sustained revenue growth
<ul>
<li>Q4 2024 unaudited revenue of approximately US$142 million (AU$218 million)1, represents an increase of 46% over the prior year corresponding quarter (Q4 2023: US$97 million or AU$148 million) and a quarter-over-quarter increase of 5% (Q3 2024: US$135 million or AU$201 million).</li>
<li>Telix's revenue is currently generated predominantly from sales of Illuccix&#xAE;, its diagnostic radiopharmaceutical for prostate cancer PET2 imaging.</li>
</ul>
Full year guidance exceeded
<ul>
<li>Total FY2024 unaudited revenue is approximately US$517 million (AU$783 million) exceeding previously stated guidance of US$490 million to US$510 million (AU$745 million to AU$776 million), representing a 55% increase over FY2023.</li>
<li>FY2024 investment into research and development (R&amp;D) remains in line with guidance, funded by earnings generated from product sales.</li>
<li>The Company intends to provide FY2025 guidance when it reports audited FY2024 annual results on 20 February 2025.</li>
</ul>

Earnings

Telix Pharma Reported Q4 Revenue Of $142M, Up 46% YoY, FY24 Revenue Of $517M, Up By 55% YoY

Elon Musk&#8216;s rocket manufacturing company SpaceX said on Saturday that it is now targeting Wednesday for its upcoming seventh flight test, later than its previous timeline of Monday.
What Happened:&nbsp;The launch window opens at 4:00 p.m. CT on Wednesday. 
SpaceX has previously said that its Starship vehicle, currently undergoing testing and development, will launch from Starbase in Texas for its seventh flight test carrying 10 Starlink simulators which are similar in size and weight to the company's next-generation Starlink satellites in a bid to demonstrate its capabilities in the satellite launch segment.
For the upcoming flight, SpaceX is looking to catch the two-stage vehicle&#8217;s booster back at the launch pad at Starbase with the launch tower&#8217;s metallic arms like on its fifth test flight in October. However, in case of any safety concerns, the company will splash it down in the Gulf of Mexico, it said.
The spacecraft, meanwhile, is slated to be splashed down in the Indian Ocean on the upcoming test.
While SpaceX has conducted 6 test flights of its ambitious launch vehicle to date, none of them carried any payload. The last test flight of Starship was in November.
Why It Matters:&nbsp;Starship is key to many big ambitions in the field of space exploration.
While NASA is looking forward to landing humans back on the surface of the Moon after a gap of over 50 years with the help of a&nbsp;<a href="https://www.benzinga.com/24/11/42108681/spacex-shows-off-conceptual-version-of-starship-which-will-help-humans-land-back-on-moon-in-over-50-yrs" target="_blank" rel="noreferrer noopener">custom version of the Starship</a>, Musk dreams of taking&nbsp;<a href="https://www.benzinga.com/news/24/09/40770222/elon-musk-sets-2026-for-starships-first-uncrewed-mars-mission-targeting-successful-landing" target="_blank" rel="noreferrer noopener">humans to the planet Mars</a>&nbsp;aboard the&nbsp;vehicle.
The last time humans set foot on the Moon was in 1972&nbsp;<a href="https://www.benzinga.com/news/24/01/36692749/just-a-worse-version-of-apollo-elon-musk-baffled-by-nasa-veterans-push-to-ditch-spacex-blue-origin-a" target="_blank" rel="noreferrer noopener">with Apollo 17</a>. Since then, no crew has traveled beyond low-Earth orbit.
SpaceX conducted a launch rehearsal with nearly 11 million pounds of propellant on Friday. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Starship and Super Heavy loaded with nearly 11 million pounds of propellant in a launch rehearsal ahead of the seventh flight test <a href="https://t.co/aSWDcEGAzn">pic.twitter.com/aSWDcEGAzn</a>
&mdash; SpaceX (@SpaceX) <a href="https://twitter.com/SpaceX/status/1877918089901421035?ref_src=twsrc%5Etfw">January 11, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/space/25/01/42868860/starships-raptor-engine-needs-few-final-touches-before-reaching-perfection-says-spacex-ceo-elon-musk" target="_blank" rel="noreferrer noopener">Starship's Raptor Engine Needs ‘Few Final Touches' Before Reaching Perfection, Says SpaceX CEO Elon Musk</a></li>
</ul>
Photo courtesy: SpaceX

SPACE

Elon Musk's SpaceX Delays Starship 7th Test Flight To Wednesday

GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST. Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment. The acquisition includes lead molecule, IDRX-42, a highly selective KIT TKI being developed as a first- and second-line therapy for the treatment of GIST.

GSK To Acquire Biopharma Firm IDRx for $1B And Earnout Of Up To $150M, Targets Precision Therapy for GIST Treatment

BHVN

MRUS

Reported Earlier, Merus And Biohaven Partner to Co-Develop Three Novel Bispecific Antibody Drug Conjugate (ADC) Programs

Daiichi Sankyo (TSE: 4568) and AstraZeneca's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NSCLC) who have received prior systemic therapies, including an EGFR-directed therapy.
Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and AstraZeneca.
The U.S. Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance. The Prescription Drug User Fee Act (PDUFA) date, the FDA action date for its regulatory decision, is July 12, 2025. Datopotamab deruxtecan was previously <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.daiichisankyo.com%2Ffiles%2Fnews%2Fpressrelease%2Fpdf%2F202412%2F20241209_E.pdf&amp;esheet=54176761&amp;newsitemid=20250110025651&amp;lan=en-US&amp;anchor=granted&amp;index=1&amp;md5=63ac3be3e8ea1b7016c6f1afe51b484f">granted</a> Breakthrough Therapy Designation (BTD) by the FDA for this patient population.
The BLA and BTD are based on data from the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04484142&amp;esheet=54176761&amp;newsitemid=20250110025651&amp;lan=en-US&amp;anchor=TROPION-Lung05&amp;index=2&amp;md5=d484a174b1fff7a915f6bcf0bbd4bf2f">TROPION-Lung05</a> phase 2 trial and supported by data from the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04656652&amp;esheet=54176761&amp;newsitemid=20250110025651&amp;lan=en-US&amp;anchor=TROPION-Lung01&amp;index=3&amp;md5=fcbf0320494ff306e884b868ba75286b">TROPION-Lung01</a> phase 3 trial. In addition, the BLA is supported by the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT03401385&amp;esheet=54176761&amp;newsitemid=20250110025651&amp;lan=en-US&amp;anchor=TROPION-PanTumor01&amp;index=4&amp;md5=8acfba8e3acccde528f9021a99489936">TROPION-PanTumor01</a> phase 1 trial. In a pooled analysis of patients with previously treated advanced or metastatic EGFR-mutated NSCLC in the TROPION-Lung05 and TROPION-Lung01 trials <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.daiichisankyo.com%2Ffiles%2Fnews%2Fpressrelease%2Fpdf%2F202412%2F20241206_E.pdf&amp;esheet=54176761&amp;newsitemid=20250110025651&amp;lan=en-US&amp;anchor=presented&amp;index=5&amp;md5=bce953e44715738b5bcad79db8943f67">presented</a> at the European Society for Medical Oncology (ESMO) Asia 2024 Congress, datopotamab deruxtecan demonstrated clinically meaningful tumor response. The safety profile of datopotamab deruxtecan was consistent with previous reports from the TROPION-Lung05 and TROPION-Lung01 trials, with no new safety concerns identified.

DSKYF

DSNKY

FDA Grants Priority Review to Daiichi Sankyo and AstraZeneca's Datopotamab Deruxtecan for Advanced Lung Cancer Treatment

<ul>
<li>Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028</li>
<li>Study 1 of Essential3 program for ulixacaltamide in essential tremor (ET) on track for Q1 2025 interim analysis; NDA filing for ulixacaltamide expected in 2025</li>
<li>Enrollment in EMBOLD study of relutrigine cohort 2 is on track; targeting NDA filing in 2026</li>
<li>Vormatrigine ENERGY program advancing with read-outs of RADIANT in first half of 2025 and POWER1 by year-end 2025</li>
<li>UCB has exercised its option to license KCNT1 small molecule candidate for global development and commercialization</li>
<li>Cash and investments ~ $470 million at the end of 2024 support runway into 2028</li>
</ul>

PRAX

Reported Earlier, Praxis Announces 2025 Milestones: Advancing Relutrigine, Ulixacaltamide, And Rare Disease Programs With $470M In Cash Reserves

Battling a legal soup in the U.S., controversial cryptocurrency-based betting platform Polymarket was refused access in another key financial market, Singapore, locals said on Sunday.
What happened: Alex Zuo, investments and custody vice president of cryptocurrency wallet provider Cobo, posted a snippet of an official notice that Singaporeans trying to use the platform were receiving.
"You have attempted to access an illegal gambling site hosted by an unlicensed gambling service provider," the notice read.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">polymarket在坡正式定义为博彩网站，想下注只能去国营博彩公司哦，否则面临罚款和坐牢哦 <a href="https://t.co/VdoozWAVgE">pic.twitter.com/VdoozWAVgE</a>
&mdash; alexzuo&#x1fae1; (@alexzuo4) <a href="https://twitter.com/alexzuo4/status/1878267006434074988?ref_src=twsrc%5Etfw">January 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The message was from Singapore's gambling regulator, the Gambling Regulatory Authority, implying that Polmarket was defined as a gambling website in the country.
The notice warned users that only the state-owned betting company could be used for gambling activities in the country, and anyone found flouting rules could face fines or even jail time.
Benzinga reached out to Polymarket and the Gambling Regulatory Authority, and the copy will be updated once they respond.
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42936962/shytoshi-kusama-outlines-treat-tokens-usefulness-ahead-of-launch-optimistic-whales-buy-up-shiba-inu">Shytoshi Kusama Outlines TREAT Token&#8217;s Usefulness Ahead Of Launch, Optimistic Whales Buy Up Shiba Inu</a>
Why It Matters: Polymarket, which rose to prominence during the U.S. election season, has been under consistent scrutiny.&nbsp;
The Polygon (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">POL</a>)-based platform is inaccessible to U.S. residents, although one can use a VPN to change one's location outside of the U.S.
There were widespread concerns over disproportionately larger bets in favor of Donald Trump leading to the election, with many pointing to <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41434026/mark-cuban-dismisses-polymarket-election-odds-as-meaningless-most-of-the-money-is-foreign">foreign influence and market manipulation</a>. The platform is inaccessible to U.S. users.
Notably, CEO Shayne Coplan's residence was <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41959476/fbi-raids-polymarket-ceo-over-crypto-betting-platforms-us-activities-he-fires-back-in-the-face-of-adversity-we-build">raided by the Federal Bureau of Investigation</a> after the election.
More recently, cryptocurrency exchange Coinbase was subpoenaed by the CFTC, where the regulator sought "general customer information" related to Polymarket.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42935597/mark-cuban-advocates-bitcoin-over-gold-during-economic-turmoil-i-think-it-has-more-value-than-gold">Mark Cuban Advocates Bitcoin Over Gold During Economic Turmoil: &#8216;I Think It Has More Value Than Gold&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Global

$POL

Singapore Cracks Down On Polymarket: Regulator Issues Warning Against 'Illegal Gambling'

<ul>
<li>Reported $2.2 billion in preliminary&#x2A; full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales</li>
<li>Pre-filled syringe FDA PDUFA on track for April 2025 to support reaching patients earlier in treatment paradigm</li>
<li>10 ongoing registrational studies in 2025 across efgartigimod and empasiprubart enable next wave of indications</li>
<li>Empasiprubart to be evaluated in two head-to-head registrational studies against IVIg to position C2 inhibitor for broad, early-line use in MMN and CIDP</li>
<li>Transition to sustainable profitability in 2025 enables continued investment in innovation</li>
</ul>

ARGX

argenx Preliminary 2024 Financial Results: $2.2B In Annual Product Sales, $737M In Q4 Revenue, And $3.4B In Cash Reserves

<ul>
<li>Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea&#xAE;1</li>
<li>Agreement builds on the proven and successful collaboration of commercialization of FYB201, Formycon's biosimilar to Lucentis&#xAE;2 (ranibizumab) in Europe</li>
<li>The partnership broadens Teva's biosimilars portfolio, in line with its Pivot to Growth strategy &nbsp;</li>
</ul>

TEVA

Teva Partners With Formycon And Klinge To Commercialize Biosimilar To Eylea In Europe And Israel

<ul>
<li>The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is the first clinically approved in-situ hybridisation (ISH) test with the sensitivity to assess the full spectrum of B-cell lymphoma subtypes.1,2</li>
<li>The test helps differentiate a B-cell cancer from a normal, reactive immune response, offering diagnostic certainty for healthcare providers and their patients.</li>
<li>B-cell lymphoma accounts for approximately 85 percent of non-Hodgkin lymphoma (NHL) cases, which is one of the most common cancers in the US.3</li>
</ul>

RHHBF

RHHBY

RHHVF

Roche's VENTANA ISH Test Secures FDA Clearance For Accurate B-Cell Lymphoma Diagnosis

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
<ul>
<li>Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa and the standard treatment Pd, improved responses and long-term outcomes compared to Pd alone in R/R MM patients</li>
<li>Sarclisa-Pd is currently recommended by the Chinese Society of Clinical Oncology (CCSCO) and Chinese Anti-Cancer Association (CACA) treatment guidelines for this patient population&nbsp;</li>
</ul>

Comments

Gateway Bank F S B

Notizie

Ultime notizie per Gateway Bank F S B (OTC:GWBK) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO